Research & Education

IASLC European Webinar Series - 2015/2016 - Surgical Standards for Non-Small Cell Lung Cancer

September 1, 2015 - 7 p.m. CEST - Recording Available
 Walter Weder

Walter Weder, MD
Chariman and Professor
University Hospital Zurich
Division of Thoracic Surgery

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

 

Name of Activity: 

 

Surgical Standards for Non-Small Cell Lung Cancer

Date of Activity:

 

09/01/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

Walter Weder, MD- Speaker- Has Nothing to Disclose

Franco Foti- Moderator- Has nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

   No

If yes, please list:

Surgical resection provides the best chance for cure for patient with early stage lung cancer and in a multidisciplinary concept in selected patients with locally-advanced disease. Dependent on stage, histology as well as functional reserves and comorbidity a tailored surgical treatment is applied. For most patients a lobectomy with a mediastinal lymphadenectomy is treatment of choice. In many centers, this is done minimal invasively with video-assisted thoracoscopy. For small size tumors located in the outer third of the lungs, a sublobar resection might be adequate. In tumors infiltrating lobar airways or the intralobar pulmonary artery, a pneumonectomy can be avoided by lung sparing resections using sleeve resection of either the bronchus or the artery with re-anastomosis of the healthy remaining lobe to the central airways or the artery. This can be done safely and the results are good provided clear margins are achieved. In cancer centers with experienced thoracic surgeons the perioperative mortality for lobectomy is less than 1 percent and for more extensive resections less than 2-3 percent. All patients should be discussed at multidisciplinary tumor boards for consideration of neoadjuvant or adjuvant treatment modalities.

Learning objectives:

  1. Illustrate the role of surgery in early and locally-advanced lung cancersStage-dependent tailored treatment
  2. Indicate of sublobar resection compared to standard lobectomy for stage I and II lung cancer
  3. Demonstrate technique of sleeve resection as lung-sparing procedure

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

The objective of this workshop was to enable fruitful collaborations that could help design a high priority biomarker-driven clinical study to assess the efficacy of a targeted-therapy in a specific lung cancer population, while helping to collect data for regulatory approval.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

 

DOWNLOAD RECORDING 

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

 

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Tuesday, September 1, 2015 at 1:00:00 PM EDT UTC-4 hours
Zurich (Switzerland) Tuesday, September 1, 2015 at 7:00:00 PM CEST UTC+2 hours
Amsterdam (Netherlands) Tuesday, September 1, 2015 at 7:00:00 PM CEST UTC+2 hours
Barcelona (Spain) Tuesday, September 1, 2015 at 7:00:00 PM CEST UTC+2 hours 
Dublin (Ireland) Tuesday, September 1, 2015 at 6:00:00 PM IST UTC+1 hour
London (England) Tuesday, September 1, 2015 at 6:00:00 PM BST UTC+1 hour
Paris (France) Tuesday, September 1, 2015 at 7:00:00 PM CEST UTC+2 hours
Vienna (Austria) Tuesday, September 1, 2015 at 7:00:00 PM CEST UTC+2 hours
Chicago (U.S.A.) Tuesday, September 1, 2015 at 12:00:00 Noon CDT UTC-5 hours
Los Angeles (U.S.A.) Tuesday, July 14, 2015 at 10:00:00 AM PDT UTC-7 hours
Corresponding UTC (GMT) Tuesday, July 14, 2015 at 5:00:00 PM     

How to use the Time Zone Converter